OS-01 Senotherapeutic Peptide Body Lotion — 61~85 Year Women IL-8 ↓ + Hydration 41% ↑. First Clinical Data for Body Skin Aging

The face-centric anti-aging cosmetics market expands to body. Journal of Cosmetic Dermatology 2026 — OS-01 senotherapeutic peptide body lotion in 12-week RCT simultaneously validated skin barrier·systemic inflammation·appearance improvement in 52 women aged 61~85. ~70% improved across all areas. Hydration up to 41% increase, IL-8 inflammatory cytokine significantly reduced, with TEWL·pH·biological age also evaluated. First clinical data for “crepey” body skin on chest·arms·abdomen·thigh.

What Is Senotherapeutic

Senotherapeutic:

• “Senescence” (cell aging) + “Therapeutic”
• Targets senescent cells·SASP (senescence-associated secretory phenotype)
• Two types:
  • Senolytic: directly removes senescent cells (fisetin·dasatinib·quercetin etc)
  • Senomorphic: suppresses senescent cell SASP secretion (keeps alive but blocks inflammation signaling)

OS-01:

• Senomorphic peptide
• Suppresses senescent cell SASP secretion
• Not direct removal but “quiets” them
• Applied to skin → ↓ epidermal·dermal aging markers

Face vs Body Aging

Face aging characteristics:

• UV·expression·gravity
• Fine lines·coarse wrinkles·pigmentation·pores
• Very large cosmetics·procedure market (tens of trillions KRW)

Body skin aging characteristics:

• “Crepey” texture (thinning and wrinkling)
• Prominent on chest·arms·abdomen·thigh·hand
• UV accumulation + hormone changes + skin barrier weakening + ↓ collagen
• Smaller market·research than face (but increasingly highlighted)

60+ women’s body skin:

• Postmenopausal estrogen ↓ → collagen ↓
• Skin barrier weakening → ↑ water loss
• Chronic inflammation (inflammaging)
• Senescent cell accumulation
• “Crepey” appearance

Journal of Cosmetic Dermatology Clinical Results

Study design:

• 52 women, average ages 61~85
• OS-01 group 27 / control 25
• 12-week double-blind randomized trial
• Applied to chest·arms·abdomen·thigh
• Measured:
  • Hydration (TEWL, transepidermal water loss)
  • Skin pH
  • Inflammatory cytokines (IL-8 etc)
  • Appearance evaluation (physician·self)
  • Biological age (DNA methylation clock)

Key results:

1. Skin barrier:

• Hydration up to 41% increase
• TEWL reduction
• pH normalization
• ~70% patients meaningful improvement

2. Systemic inflammation (skin-measured):

• IL-8 cytokine significant reduction
• Inflammation circuit blockade
• SASP suppression consistent

3. Appearance:

• “Crepey” texture improvement
• ↓ wrinkles
• Physician·self evaluation aligned
• ~70% improvement

4. Biological age:

• DNA methylation-based evaluation
• Some patients showed ↓ biological age signal (small but statistically significant)

5. Safety:

• Zero side effects over 12 weeks
• All patients completed (no dropouts)

OS-01 Mechanism

Senescent cell·SASP control:

1. Peptide penetrates skin epidermis·dermis
2. Binds senescent cell surface receptors
3. Blocks SASP secretion signaling circuit (NF-κB·SASP pathway)
4. ↓ inflammatory cytokines (IL-6·IL-8·TNF-α)
5. Result: skin barrier recovery·appearance improvement

Senolytic vs Senomorphic difference:

Aspect	Senolytic	Senomorphic (OS-01)
Action	Remove senescent cells	Calm senescent cells (↓ SASP)
Effect intensity	Strong	Medium
Safety	Some concerns (normal cell impact)	↑ safety
Application	Pharmaceutical (fisetin·dasatinib)	Cosmetic·functional

Face vs Body Anti-Aging Matrix

Face matrix (already strong):

• Retinol (L65 new retinol 76% improvement)
• Vitamin C·niacinamide
• Peptides
• Sunscreen
• Peeling·laser procedures

Body matrix (expanded by this study):

• Senotherapeutic body lotions like OS-01
• Collagen peptides
• AHA·BHA body (exfoliation)
• Body sunscreen (often forgotten but important)
• Moisturizers (ceramide·squalane·shea butter)

Female Impact — 60+ Body Skin

60+ women’s body burden:

• Postmenopausal estrogen ↓ → skin collagen ↓
• Skin thinning → bruising·abrasion from light impact
• Self-perception ↓ from chest·arm·abdomen·thigh appearance changes
• Medical: ↑ pressure ulcer·delayed wound healing·infection risk

What OS-01 means:

• Not pharmaceutical (no physician prescription)
• Clinical data in cosmetic territory
• Senescent cell·SASP target expands from face to body
• Meaningful option for 60+ women

Commercial Products·Access

OS-01-containing products:

• OneSkin (company) body lotion·face cream
• Available in US·EU some countries
• Pricing: 100ml $80120

Korean introduction:

• Direct purchase·online (US·Europe)
• Korean MFDS formal introduction expected post-2027
• Pricing: ₩100,000150,000/100ml

Alternative senotherapeutic cosmetics:

• Some K-beauty brands attempting senolytic·senomorphic
• But clinical data not as strong as OS-01
• Market gradually expanding

Natural Matrix — Senescent Cell Integrated Management

Diet:

• Antioxidants (berries·green tea·dark chocolate)
• Fisetin-containing foods (strawberry·apple·cucumber) — L63 senolytic
• Omega-3 EPA/DHA 1~2 g/day
• Vitamin C·E
• Polyphenols

Supplements:

• Fisetin (L63 TROFFi 100mg/kg)
• Collagen peptides
• Vitamin D
• Magnesium

Lifestyle:

• Daily body sunscreen (not just face)
• No smoking·↓ heavy drinking
• Adequate sleep
• Regular exercise
• ↓ chronic stress

Korean Clinical Significance

Korean 60+ women:

• Rapid population aging
• Beauty·wellness market 60+ area rapidly expanding
• But ↓ body skin care options (mostly face-focused)

OS-01 Korean introduction outlook:

• Direct purchase·online active
• Korean MFDS cosmetic notification expected 2027
• Pricing entry barrier (₩100,000~150,000 ×2 bottles/month)

Conclusion

OS-01 senotherapeutic peptide body lotion’s 12-week RCT provides first clinical data of senescent cell·SASP target expanding from face to body. In 61~85 year women, 70% improvement + hydration 41% ↑ + IL-8 ↓. New option for postmenopausal women’s “crepey” body skin. With L63 fisetin senolytic + L67 OS-01 senomorphic, two-approach matrix to senescent cells built. Entry into precision anti-aging era where pharmaceutical (fisetin) and cosmetic (OS-01) share the same target (senescent cells).